Computational drug discovery approaches identify mebendazole as a candidate treatment for autosomal dominant polycystic kidney disease.

Philip W Brownjohn¹, Azedine Zoufir¹, Daniel J O'Donovan¹, Saatviga Sudhahar¹, Alexander Syme¹, Rosemary Huckvale¹, John R Porter¹, Hester Bange², Jane Brennan¹, Neil T Thompson¹

¹Healx Ltd., Cambridge, United Kingdom.

²Crown Bioscience Netherlands B.V., Biopartner Center Leiden JH, Leiden, Netherlands.

PubMed PMC DOI PDF

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a rare genetic disorder characterised by numerous renal cysts, the progressive expansion of which can impact kidney function and lead eventually to renal failure. Tolvaptan is the only disease-modifying drug approved for the treatment of ADPKD, however its poor side effect and safety profile necessitates the need for the development of new th…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.